Form 6-K Ascendis Pharma A/S For: Nov 13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Tesla acquires AI hardware company for up to $2 billion in stock
Ascendis Pharma (ASND) PT Lowered to $200 at Citi
November 15, 2024 7:10 AM ESTCiti analyst David Lebowitz lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $200.00 (from $207.00) while maintaining a Buy rating.
The analyst comments "Ascendis reported 3Q24 financial results, missing Street estimates on topline revenue and GAAP EPS, as the Skytrofa challenges that emerged... More
Ascendis Pharma (ASND) PT Lowered to $180 at Oppenheimer
November 15, 2024 6:21 AM ESTOppenheimer analyst Leland Gershell lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $180.00 (from $190.00) while maintaining a Outperform rating.
The analyst comments "ASND reported 3Q net loss of 99.2M vs. our expected 110.2M as management continues to effectively manage expenses. Skytrofa revenue of... More
